Diese Präsentation wurde erfolgreich gemeldet.
Wir verwenden Ihre LinkedIn Profilangaben und Informationen zu Ihren Aktivitäten, um Anzeigen zu personalisieren und Ihnen relevantere Inhalte anzuzeigen. Sie können Ihre Anzeigeneinstellungen jederzeit ändern.
Pharmaceutical Industry Financial Analysis<br />FE 449: Corporate Finance<br />James Potts<br />Richard Su<br />Hin Mok<br...
Industry Highlights<br />2009 Industry Sales: $300.3B<br /> Brand Name vs. Generics<br />Patents<br />High Fixed Costs<br ...
Research & Development<br />The pharmaceutical industry is the most research-intensive in the US.<br />FY2009: Over $65.3 ...
Consolidation and M&A<br />Big pharmaceuticals look to diversify products as well as gain valuable IP rights, expertise, c...
Firm Valuation Overview<br />
Eli Lilly <br />Based in Indiana<br />History of success with anti-depressants <br />Notable Former Board Members<br />Geo...
DCF: Growth vs. Discount Rate<br />
Eli Lilly <br />
AstraZeneca (NYSE: AZN)<br />Incorporated in 1992, based in the UK<br />Focused on the discovery, development, and commerc...
AstraZeneca Major Products<br />Focused in 6 areas of healthcare<br />10 drugs each over $1B in revenues annually in 2009<...
AstraZeneca Valuation<br />Compared with Pfizer, Abbott, Roche, Novartis, GlaxoSmithKline<br />EBITDA<br />Represents prof...
Bristol Myers<br />Headquartered in New York City<br />11 Key drugs,<br />Plavix<br />7 drugs in phase III as of 2009<br /...
Bristol Myers<br />Compared with: Pfizer, Gilead, Baxter, Eli Lilly, and Amgen<br />BEV/REV = $25.38<br /> BEV/EBITDA = $2...
Pfizer, Inc. (NYSE: PFE)<br />The largest prescription drug manufacturer worldwide<br />Holds a diversified arm that also ...
Notable Events<br />Pfizer acquired Wyeth in 2009 for over $64 B.<br />Beneficial through legacy products, expertise, capa...
Pfizer Valuation<br />CompCo: <br />BEV/EBITDA: $23.18<br />BEV/REV: $21.74<br />CompM&A:<br />BEV/EBITDA: $27.97<br />BEV...
Thanks for your time!<br />Questions?<br />Comments?<br />
Nächste SlideShare
Wird geladen in …5
×

Pharmaceutical Industry Financial Analysis

This is a presentation that was completed for my Corporate Finance class my senior year with a team of three other students. I did my valuation of Eli Lilly.

  • Als Erste(r) kommentieren

Pharmaceutical Industry Financial Analysis

  1. 1. Pharmaceutical Industry Financial Analysis<br />FE 449: Corporate Finance<br />James Potts<br />Richard Su<br />Hin Mok<br />Emily Wu<br />
  2. 2. Industry Highlights<br />2009 Industry Sales: $300.3B<br /> Brand Name vs. Generics<br />Patents<br />High Fixed Costs<br />Lengthy Drug Development Cycle<br />Consolidation by M&A<br />Bio-tech<br />
  3. 3. Research & Development<br />The pharmaceutical industry is the most research-intensive in the US.<br />FY2009: Over $65.3 Billion invested in R&D<br />Constantly striving to produce more drugs<br />Est. $1B spent in R&D per drug under development.<br />
  4. 4. Consolidation and M&A<br />Big pharmaceuticals look to diversify products as well as gain valuable IP rights, expertise, capacity, etc<br />Biotech and big pharmaceuticals have driven M&A over the past year<br />Alliances to overcome economy, innovate<br />Recent notable M&A’s:<br />Wyeth > Pfizer, $64B<br />Schering-Plough > Merck, $47B<br />Genentech > Roche Holdings, $44B<br />
  5. 5. Firm Valuation Overview<br />
  6. 6. Eli Lilly <br />Based in Indiana<br />History of success with anti-depressants <br />Notable Former Board Members<br />George H.W. Bush<br />Kenneth Lay<br />
  7. 7. DCF: Growth vs. Discount Rate<br />
  8. 8. Eli Lilly <br />
  9. 9. AstraZeneca (NYSE: AZN)<br />Incorporated in 1992, based in the UK<br />Focused on the discovery, development, and commercialization of prepared medicines.<br />7th largest pharmaceutical company based off revenues<br />Operated in over 100 countries<br />
  10. 10. AstraZeneca Major Products<br />Focused in 6 areas of healthcare<br />10 drugs each over $1B in revenues annually in 2009<br />60 major R&D collaborations last three years<br />
  11. 11. AstraZeneca Valuation<br />Compared with Pfizer, Abbott, Roche, Novartis, GlaxoSmithKline<br />EBITDA<br />Represents profit of business when only considering operations<br />Good way to predict growth of business<br />
  12. 12. Bristol Myers<br />Headquartered in New York City<br />11 Key drugs,<br />Plavix<br />7 drugs in phase III as of 2009<br />Focused on<br />Cancer<br />HIV/AIDS<br />Cardiovascular<br />diabetes<br />
  13. 13. Bristol Myers<br />Compared with: Pfizer, Gilead, Baxter, Eli Lilly, and Amgen<br />BEV/REV = $25.38<br /> BEV/EBITDA = $25.28<br />Price/Sales = $24.79<br />Plavix exclusive loss in US in 2011 and in Canada in 2012<br />Avapro exclusive loss in US 2012 and in Europe in 2013<br />
  14. 14. Pfizer, Inc. (NYSE: PFE)<br />The largest prescription drug manufacturer worldwide<br />Holds a diversified arm that also manufactures drugs for animals, as well as gelatin capsules<br />Notable products: Lipitor, Viagra, Celebrex<br />
  15. 15. Notable Events<br />Pfizer acquired Wyeth in 2009 for over $64 B.<br />Beneficial through legacy products, expertise, capacity, savings on R&D.<br />Result: on pace to grow in FY2010 over 50% versus FY2009 (3.55%)<br />
  16. 16. Pfizer Valuation<br />CompCo: <br />BEV/EBITDA: $23.18<br />BEV/REV: $21.74<br />CompM&A:<br />BEV/EBITDA: $27.97<br />BEV/REV: $21.86<br />DCF: $44.54<br />High due to unpredictability of extraordinary items, Wyeth legacy products<br />Blended Price: $26.34<br />
  17. 17. Thanks for your time!<br />Questions?<br />Comments?<br />

×